CULLINAN THERAPEUTICS, INC. (CGEM) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 78.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $78.64M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $75.08M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $88.33M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $103.33M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $72.82M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $76.66M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $83.00M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $102.08M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $115.02M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $74.23M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $98.43M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $64.85M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $141.83M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $122.13M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $156.15M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $242.66M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $353.56M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $76.12M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $59.77M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $88.11M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $123.67M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $293.54M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $168.20M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |